Treprostinil for intermediate-risk pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of pulmonary arterial hypertension (PAH) from specific causes (not from other heart or lung diseases).
- You must have had a right heart catheterization within the past 6 months that shows certain pressure levels in your lungs.
- You must be in functional class II, III, or IV, which describes how much your symptoms limit your daily activities.
- You must be on a stable dose of certain PAH medications (like bosentan or sildenafil) for at least 30 days, or be willing to start one in addition to the study drug.
- You must not be on any other prostacyclin-type drugs (like epoprostenol or selexipag) within 30 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well treprostinil, a medication given by injection, works for people with pulmonary hypertension. It aims to gather real-world data to understand treatment trends and outcomes.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
This study tests a new drug, tiprelestat, added to your current treatment for pulmonary arterial hypertension (PAH). It aims to see if it improves your symptoms and exercise ability.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.